REGENERON PHARMACEUTICALS INC. - COMMON STOCK

673.60

14-February-25 15:45:00

15 minutes delayed

Stocks

-0.67

-0.10%

Today's range

671.55 - 684.00

ISIN

N/A

Source

NASDAQ

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

26 Sep 2024 15:05:00 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

20 Sep 2024 06:45:00 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

13 Sep 2024 11:15:28 By Nasdaq GlobeNewswire
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

11 Sep 2024 06:00:46 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

11 Sep 2024 00:04:00 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

10 Sep 2024 23:59:00 By Nasdaq GlobeNewswire
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

09 Sep 2024 16:00:00 By Nasdaq GlobeNewswire
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO

09 Sep 2024 06:00:17 By Nasdaq GlobeNewswire
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

27 Aug 2024 09:44:05 By NetDania Notify
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 Aug 2024 12:12:44 By NetDania Notify
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

26 Aug 2024 06:00:00 By Nasdaq GlobeNewswire
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases

26 Aug 2024 00:00:00 By Nasdaq GlobeNewswire
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

21 Aug 2024 08:56:19 By NetDania Notify
Regeneron Provides Update on Biologics License Application for Linvoseltamab

20 Aug 2024 17:45:05 By Nasdaq GlobeNewswire
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

20 Aug 2024 08:47:18 By NetDania Notify
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

19 Aug 2024 08:50:04 By NetDania Notify
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

16 Aug 2024 10:58:01 By NetDania Notify
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

15 Aug 2024 08:45:08 By NetDania Notify
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

14 Aug 2024 09:27:20 By NetDania Notify
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 Aug 2024 08:50:04 By NetDania Notify

<<
<
1
2
3
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.